CD19 Enrichment: Targeting B Cell Immunotherapy with Precision
What is CD19?
CD19 is a transmembrane glycoprotein expressed almost exclusively on B cells throughout their development—except on plasma cells. It acts as a co-receptor with the B cell receptor (BCR) and plays a crucial role in B cell activation, proliferation, and differentiation.
Why is CD19 Important?
Due to its lineage-specific expression and stable presence on malignant B cells, CD19 serves as a reliable biomarker and therapeutic target in:
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia (CLL)
What is CD19 Enrichment?
CD19 enrichment is the process of isolating CD19-positive B cells from blood or bone marrow samples using immunomagnetic separation or flow cytometry. This is essential for both research and clinical applications, such as CAR-T cell development and disease monitoring.
Applications of CD19 Enrichment
- CAR-T Cell Therapy: Targeting CD19 with CAR-T cells for treating relapsed/refractory B-cell malignancies.
- B Cell Functional Assays: Studying signaling, antibody production, or cytokine profiles.
- Autoimmune Disease Research: Examining CD19+ B cells in diseases like lupus and rheumatoid arthritis.
- Transplantation Studies: CD19 monitoring in bone marrow transplantation for graft purity and relapse detection.
Genestac’s CD19 Enrichment Services
Genestac Therapeutics provides industry-leading CD19+ B cell enrichment services for translational research and immunotherapy workflows:
- High-purity magnetic bead-based or FACS sorting
- Viability and phenotypic confirmation (CD19, CD20, CD27)
- Compatible with downstream culture, sequencing, or reprogramming
- Fast turnaround time and scalable volumes
CD19 in CAR-T Cell Therapy: A Game Changer
CD19 has revolutionized cancer treatment through CAR-T cell therapy (e.g., Tisagenlecleucel, Axicabtagene ciloleucel). Enriched CD19-positive targets are essential for validating CAR constructs and conducting preclinical cytotoxicity assays.
FAQs on CD19
Is CD19 expressed on all B cells?
CD19 is expressed from early B cell development through mature B cells, but not on plasma cells.
Can CD19 be used as a target in autoimmune disease?
Yes. Depleting CD19+ B cells is an emerging approach in treating autoimmune diseases like SLE and MS.
Conclusion
CD19 is a pivotal biomarker in modern immunology and oncology. Whether for CAR-T development or fundamental research on B cell function, Genestac’s CD19 enrichment solutions provide the specificity and reliability you need for impactful outcomes.